Squarepoint’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.55M Buy
24,180
+5,144
+27% +$469K ﹤0.01% 2399
2025
Q4
$2.48M Sell
19,036
-58,809
-76% -$8.07M ﹤0.01% 1910
2025
Q3
$8.39M Buy
77,845
+65,228
+517% +$7.11M 0.01% 1167
2025
Q2
$1.16M Buy
+12,617
New +$990K ﹤0.01% 2526
2025
Q1
Sell
-11,989
Closed -$921K 5511
2024
Q4
$921K Sell
11,989
-34,840
-74% -$2.43M ﹤0.01% 3141
2024
Q3
$1.99M Sell
46,829
-13,120
-22% -$443K ﹤0.01% 2074
2024
Q2
$1.57M Buy
59,949
+33,293
+125% +$631K ﹤0.01% 2228
2024
Q1
$243K Buy
+26,656
New +$160K ﹤0.01% 3517
2023
Q4
Sell
-38,403
Closed -$140K 4566
2023
Q3
$140K Buy
38,403
+18,666
+95% +$102K ﹤0.01% 3506
2023
Q2
$118K Buy
+19,737
New +$156K ﹤0.01% 3330
2022
Q3
Sell
-2,227
Closed -$93K 3498
2022
Q2
$93K Sell
2,227
-1,627
-42% -$110K ﹤0.01% 2630
2022
Q1
$390K Buy
3,854
+3,078
+397% +$342K ﹤0.01% 2147
2021
Q4
$114K Buy
+776
New +$173K ﹤0.01% 2887

Other funds holding WGS

Squarepoint's WGS Position: Q1 2026 in Review

Squarepoint increased its GeneDx Holdings (WGS) stake by 27% in Q1 2026, buying an estimated $469K and bringing the position to 24,180 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Squarepoint first reported a position in WGS in Q4 2021 and has held it in 13 quarters since. The position peaked at $8.39M in Q3 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Squarepoint held 24,180 shares of GeneDx Holdings worth $1.55M as of Q1 2026.
  • Squarepoint bought 5,144 GeneDx Holdings shares in Q1 2026, an estimated $469K.
  • GeneDx Holdings made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2399 holding.
  • Squarepoint first reported a position in GeneDx Holdings in Q4 2021 and has held it in 13 quarters since.
  • Squarepoint's GeneDx Holdings position peaked at $8.39M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.